Kry

1.1 Identity and operating model

Kry is described across the retained evidence as a private digital-health company that combines online consultations with physical primary and specialist care. Tracxn characterizes it as a provider of “digital and physical primary urgent and secondary care,” while the Index Ventures job-board profile says the business is headquartered in Stockholm and operates as Kry in Sweden and Norway and Livi in the UK and France. Sacra describes three revenue streams—consultation fees, SaaS sales to clinicians and clinics, and referral payments from partners. The operating model is therefore broader than a video-visit application: it spans consumer and payer relationships, clinical operations, clinics, and healthcare workflow software.[CO001, CO002, CO003, CO004]

1.2 Leadership, governance, and dependencies

Tracxn and Scalable identify Kalle Conneryd-Lundgren as chief executive, while EquityZen still identifies co-founder Johannes Schildt as CEO and GetLatka uses the name Karl Conneryd-Lundgren. The evidence therefore supports a current operating-leadership hypothesis but not a fully reconciled executive chronology. Scalable names Johannes Schildt, Josefin Landgård, Fredrik Jung Abbou, and Joachim Hedenius as founders and describes Schildt as chairman. None of the retained sources provides a complete current board, voting structure, liquidation preferences, or succession plan. Governance and key-person exposure remain only partially observable and require primary company records.[CO005, CO006, CO007]

1.3 Capital, scale, and KPI visibility

Kry’s capital history is substantial but inconsistent across databases. Tracxn reports $703 million across seven rounds and a $160 million Series D on 21 July 2022, while GetLatka reports $627 million across three rounds. Public profiles also repeat a $2 billion historical valuation but attach it to different financing dates. The different totals and round counts may reflect scope or database methodology rather than a reconciled financing history. Sacra estimates $258 million of 2024 revenue, while GetLatka lists $232 million for December 2024 without recording its source; neither is an audited group statement in the retained pool. Current customer count and comparable physical-footprint metrics remain gaps.[CO008, CO009, CO010, CO011, CO012, CO013, CO014]

1.4 Milestones and unresolved diligence

The dated record shows a digital-health launch in 2014, a 2015 founded-year record, a $2 billion financing-era valuation in 2021 or 2022, and continuing scale signals through 2026. A Care Quality Commission report published 29 November 2024 rates Kry UK “Good” across safety, effectiveness, care, responsiveness, and leadership. That is a useful regulated-service signal, not proof of group-wide quality or economics. UpMarket separately highlights capital intensity and dependence on utilization, reimbursement, and cost control. The public evidence still does not establish consolidated profitability, cash, debt, runway, current valuation, or a complete adverse-event register.[CO001, CO002, CO008, CO010, CO013, CO015, CO016]

1.5 Exhibits

2.1 Market boundary and evidence-constrained sizing

Kry sits inside a narrower market than broad digital health: hybrid primary-care delivery, patient navigation, and provider workflow services sold through public systems, insurers, employers, and direct-access channels. IQVIA's 337,000-app universe and its counts for software-based therapies and diagnostics describe adjacent supply, not Kry's addressable revenue pool. Kry's own scale claims and Dealroom's workforce signal establish operating reach, but neither supplies a payer-spend denominator. The correct investment conclusion is therefore a constrained sizing case rather than a top-down TAM. France's public health-data portal is a logical diligence path, yet its landing page does not expose a usable utilization or spending series. A defensible SAM still requires country-level primary-care spend, eligible encounter volumes, reimbursement rates, and the share of pathways that can safely move into hybrid care.[CM001, CM002, CM006, CM007, CM008, CM009, CM016]

2.2 Buyers, payers, and adoption path

The user is the patient or clinician, but the economic buyer varies by channel. Sacra described national payers paying per service or per enrolled citizen, while Kry also reaches patients through GP practices, public apps, insurers, and employers. That mix makes distribution and reimbursement as important as consumer demand. Company-supplied evidence points to substantial utilization and claims that digital consultations can cost less than in-person appointments, but those claims are not independently audited market-size evidence. Adoption should be modeled as a sequence: secure a payer or practice route, integrate with the clinical front door, triage patients into an appropriate channel, prove access and cost outcomes, and then expand covered pathways. Each step narrows the serviceable opportunity and introduces a different budget owner.[CM003, CM004, CM005, CM011, CM014, CM015]

2.3 Growth drivers, constraints, and valuation relevance

Structural demand is supported by clinician workload, limited access, chronic disease, and payer interest in digital routing, while the expanding digital-care product base shows sustained innovation. Commercial conversion is less certain. IQVIA records reimbursement losses and bankruptcies among digital therapeutics, evidence that approval or availability does not guarantee durable adoption. The NHS digital-access framework also requires integration, governance, rapid response, urgent-request safeguards, and continued non-digital access, so software alone does not remove operating complexity. EHDS can lower cross-border friction over time through common data and EHR rules, but its main obligations phase in through 2029 and 2031 and impose security and interoperability requirements. Valuation should therefore reward contracted payer access and verified unit economics, not multiply a generic digital-health TAM by an assumed share.[CM007, CM008, CM009, CM010, CM011, CM012, CM013]

2.4 Exhibits

3.1 The competitive set spans operators, software, and the status quo

Kry's buyer can choose among a hybrid care operator, a focused telehealth provider, a digital-access or practice-management platform, and existing public-system channels. Low-reputation aggregators name Babylon Health, Teladoc, Push Doctor, Doktor.se, and TeleClinic as alternatives, but those lists are directional rather than an exhaustive benchmark. More concrete evidence shows Docplanner selling an ecosystem for patients, doctors, and clinics, while eConsult addresses the UK digital front door. Historical Swedish evidence also shows that Kry began as a video-only model inside a publicly reimbursed system. The landscape is therefore country- and workflow-specific: a platform can compete for patient acquisition or provider workflow without assuming Kry's clinical delivery obligations.[CP001, CP002, CP006, CP012, CP013]

3.2 Kry has meaningful hybrid scale, but comparisons are not normalized

The retained sources support operational breadth, not a clean market-share ranking. TechArena reported approximately 60 physical care centers in Sweden and three in France in March 2024. Dealroom's current profile maps 929 employees across 14 countries and estimates 350,000 monthly web visits, mostly from Sweden; these are platform estimates, not audited company disclosures. A separate profile describes Kry's scope as app, video, and chat consultations, physical clinics, specialist care, and provider tools in four European markets. Docplanner, by contrast, claims 25 million monthly appointments and 300,000 active doctors across 13 countries, but those marketplace metrics do not measure delivered consultations on a comparable denominator.[CP003, CP007, CP008, CP010, CP013]

3.3 Integration and regulated delivery matter more than a video interface

Kry's company-issued job description says its mature SARA EMR connects with e-prescription systems, population registries, SMS gateways, and appointment-booking platforms. That integration depth can create implementation and data-migration friction, but it is also a procurement requirement that capable rivals can meet. eConsult's account of the October 2025 NHS GP contract says online tools must integrate with the NHS App and clinical systems, respond within one working day, and coexist with face-to-face and telephone channels. CQC's November 2024 page rates Kry UK's service Good across five inspection dimensions. This is credible regulatory proof of delivery, but not evidence of superior outcomes, retention, or pricing versus competitors.[CP009, CP011, CP012]

3.4 The moat is operational, while the category keeps broadening

The evidence indicates that Kry's defensible position rests on operating hybrid care, embedding clinical workflow, and satisfying regulated-service requirements rather than owning a unique virtual-consultation feature. TechArena reported country-level profitability milestones alongside continuing group-level losses in 2024, illustrating both local operating progress and the cost of the broader platform. IQVIA reports that digital-health companies have faced weaker funding, revenue-growth difficulty, and bankruptcies, even as vendors combine patient- and physician-facing tools into solutions designed for health-system adoption. This broadening product frontier favors Kry's integrated model, but it also lets workflow platforms and AI-enabled entrants converge on parts of its proposition. Comparable contract economics remain the central diligence gap.[CP004, CP005, CP014, CP015, CP016]

3.5 Exhibits

4.1 Revenue architecture and traction

Kry monetizes a hybrid care platform rather than a single software SKU. Sacra describes three mechanisms: video consultations paid by national payers on fee-for-service or subscription terms, a telehealth SaaS product sold to doctors, and referral payments from pharmacies and laboratories (SI011). That mechanism mix matters because payer reimbursement and clinician utilization drive economics differently from software-seat revenue. Sacra reports a 78% Sweden, 12% UK, and 10% France revenue mix, while also describing a 50/50 split between fee-for-service and capitated subscription models; these are different denominators or periods and should not be combined into one waterfall (SI011). The same source estimates $215M revenue in 2022 and reports $164M in 2021 revenue, whereas GetLatka lists $232M annual revenue for December 2024 but explicitly says its source is not recorded (SI009). These figures are useful directional signals, not a reconciled revenue history. The operating footprint is also hybrid: Kry's company job material says it combines digital and physical care, while the CQC record confirms a UK service offering remote triage and medical advice (SI005, SI010). Underwriting should therefore separate reimbursed clinical volume, subscription enrollment, SaaS revenue, and referral revenue before applying any software multiple. [CI001, CI002, CI003, CI004]

4.2 Pricing, GTM, and sales-efficiency proxies

Public pricing is not a consumer list-price story. An early independent case study says KRY received public reimbursement and that patient pricing was the same as physical-clinic visits in Sweden (SI004). Sacra's later account adds that national payers can pay per service or through a monthly subscription for enrolled citizens, while doctors may buy a telehealth SaaS product (SI011). This implies at least three commercial motions: public reimbursement, contracted or capitated payer access, and professional software. The evidence does not disclose realized rates, discounts, payer contract duration, renewal, CAC, payback, or channel take rates. A company job repost confirms a mature SARA EMR platform with external integrations and a regulated-care workflow, which can support retention but does not prove pricing power or margin (SI005). The practical sales-efficiency proxy is operational throughput: Techarenan reports that administrative work per patient-doctor interaction was streamlined by approximately 30% after AI adoption, but the same article says group-level financials remained unprofitable (SI012). This is an efficiency signal, not CAC payback or gross-margin evidence. The revenue model bridge below therefore shows the causal path from enrolled or visiting patients to payer and provider revenue without inventing conversion rates. [CI005, CI006, CI007, CI008]

4.3 Cost structure and unit-economics visibility

The cost base is structurally labor- and compliance-heavy. Kry's public job material describes clinicians, software engineers, data specialists, regulated data models, integrations, testing, security, and audit trails; these are operating requirements rather than separately disclosed cost lines (SI005). EUJobs publishes broad, indicative compensation bands by seniority, but those ranges are a low-confidence labor-cost proxy, not Kry payroll evidence (SI002). Techarenan states that country-level profitability coexisted with group-level unprofitability because of technology investment (SI012). Sacra's analysis reports $123M of losses against $164M revenue, citing Swedish filings, but its 2023 publication date means the figure is historical rather than current (SI011). Scalable reports 2024 EBITDA of minus SEK 505M, while a 2026 SWOT assessment still characterizes Kry as loss-making with high cash burn and thin margins in publicly funded consultations (SI006, SI001). These sources point to clinician delivery, clinic overhead, customer acquisition, technology, and regulatory costs as the principal drivers, but no public source in this pool supplies contribution margin by market, clinician utilization, visit-level gross profit, or a reconciled group cash-flow statement. Every missing unit-economics field is therefore an explicit diligence request rather than a modeled zero. [CI009, CI010, CI011, CI012, CI016]

4.4 Capital adequacy and underwriting verdict

Kry has raised substantial private capital, but funding raised is not cash available. UpMarket describes the company as private, cites the April 2021 Series D at a $2B post-money valuation, and flags capital intensity, utilization, reimbursement dynamics, and cost control as risks (SI008). GetLatka lists $627M raised across three rounds and a $2B July 2022 valuation, but says its 2024 revenue source is not recorded (SI009). EquityZen confirms that secondary-market access comes from existing shareholders rather than a company-issued financing (SI007). None of these sources provides current cash, debt, covenants, burn, runway, financing terms, or a next-round trigger. The financial verdict is therefore conditional: the platform may be approaching market-level profitability in selected geographies, yet group underwriting remains blocked until management supplies a current cash bridge, debt schedule, market-level contribution margins, and reconciled revenue by stream and geography. [CI013, CI014, CI015]

4.5 Exhibits

5.1 Product surface and workflow

Kry's customer-facing product is a digital healthcare access layer: its official site says patients can see a doctor, nurse or psychologist online within minutes, while also describing integration of primary, urgent and secondary care with digital and physical care. The earlier HBS case describes video-only appointments, drop-in or future sessions, diagnosis, prescriptions where appropriate and referrals to laboratories or specialist clinics. These sources establish the patient workflow, but do not establish clinical outcomes or realized time savings. Kry's public employer material also describes a separate clinician and administration workflow through the SARA EMR platform, indicating that the product is not merely a video front end. The combination creates a coherent access-to-care workflow, while leaving the payer, triage and escalation logic to be verified in diligence.[CE001, CE002, CE003, CE004, CE005, CE016]

5.2 Operating architecture and maturity

The strongest technical evidence is the Software Engineer specification for Kry's Healthcare Systems Team. It names SARA as a mature enterprise healthcare platform serving clinicians and patients across Sweden, with Windows Forms, ASP.NET web portals, backend services and SQL Server databases. It also names integrations with e-prescription systems, population registries, SMS gateways and appointment booking platforms. This is a credible operating-architecture signal because it is tied to a concrete engineering role, although it is still a company job posting rather than an independent technical audit. The same posting calls for code reviews, comprehensive tests, data security, audit trails and compliance, which indicates control requirements but does not prove that controls are effective. Kry's official page separately claims that digital and physical care are integrated across markets; the public record does not expose service-level objectives, incident history, penetration-test results or integration uptime.[CE006, CE007, CE008, CE009, CE010, CE011]

5.3 Differentiation, trust and diligence gaps

Kry's differentiator is an operating model rather than a disclosed proprietary algorithm: the company combines patient access, clinician workflows, physical clinics and health-system relationships. The HBS case reports that Kry used centralized digital documentation and claimed lower state cost per patient, but those statements are historical case analysis and are not current audited performance evidence. IQVIA's 2024 market review shows that digital care is becoming more mature while funding, reimbursement and commercial adoption remain difficult across the sector; that context raises the bar for proving clinical utility, reimbursement durability and operational efficiency. The product thesis is therefore credible at the workflow level, but underwriting should not assume that scale, app features or integration breadth equal defensible IP, regulatory clearance, security assurance or positive unit economics. The highest-value next evidence is a current system architecture pack, security and privacy attestations, incident and uptime history, clinical quality metrics, and deployment-level outcomes by market.[CE012, CE013, CE014, CE015]

5.4 Exhibits

6.1 Patient reach spans direct digital access and hybrid care

Kry's customer surface is broader than a direct-to-consumer telehealth app. Historical evidence places the service across five European markets under the Kry and Livi brands, while current app listings explicitly cover Sweden and Norway. In Sweden, the company now presents a hybrid offer: patients can enter through chat or video, visit one of 34 health centres, or move into specialist and follow-up care. Public reimbursement has historically made the patient price comparable with a physical clinic, and third-party descriptions also position public and private healthcare professionals as ecosystem partners. These sources identify patients, clinicians, and health systems as users or counterparties, but they do not disclose which party bears revenue by market or channel. Segment economics therefore remain an underwriting gap rather than an inferred mix.[CU004, CU006, CU012, CU013]

6.2 Cumulative adoption is credible, but period activity is not disclosed

The available milestones show a large increase in reported use: more than 100,000 users in 2017, 1.4 million completed patient meetings by January 2020, and 14 million cumulative care meetings on the current Swedish site. The 2017 release also said Kry served more than 1% of Swedish primary care and employed more than 200 doctors. Current marketplace signals add 280,000 iOS ratings at 4.9 out of 5 and a company-reported service level in which 80% of patients received help within 23 minutes. These metrics have different denominators and periods: cumulative meetings are not active patients, ratings are not visits, and web traffic is not paid utilization. Dealroom's 350,000 monthly visits, 90.5% attributed to Sweden, are best treated as a directional channel- concentration proxy rather than a customer count.[CU001, CU002, CU003, CU005, CU007, CU008, CU010, CU011]

6.3 Regulatory and marketplace proof exists; retention proof does not

The strongest external quality evidence is the Care Quality Commission's November 2024 report for Kry UK, which rated the service Good for safe, effective, caring, responsive, and well-led care. App Store volume and rating provide a broad consumer-sentiment signal, while historical investor releases document adoption milestones. None of these measures establishes renewal, gross or net revenue retention, repeat consultation frequency, or institutional contract duration. Nor does the assigned evidence disclose named NHS, insurer, employer, or regional-system accounts with contract value and renewal outcomes. Public proof therefore supports real patient use and regulated service delivery, but not commercial durability. The named-proof exhibit is deliberately a partial sample of verifiable cohorts and service evidence, not a customer roster.[CU001, CU003, CU007, CU009, CU015]

6.4 Hybrid continuity creates expansion paths, with unresolved channel risk

Kry's disclosed journey can move a patient from app-based booking and triage to a clinician consultation, prescription or referral, physical care when needed, and follow-up. The SARA electronic medical record job description says the platform serves thousands of patients and clinicians daily, indicating that the operational surface extends beyond a consumer front end. The hybrid model could deepen engagement across primary, specialist, mental-health, and chronic-care needs, but the pool offers no cohort evidence that this pathway improves repeat use or economics. A historical HBS analysis also cautioned that claimed relief of clinician shortages could be contested if professionals move from physical clinics to Kry. Management diligence should therefore reconcile channel-level revenue, clinician utilization, payer concentration, and repeat-use cohorts before treating cumulative meetings as durable expansion.[CU011, CU014, CU015, CU016]

6.5 Exhibits

7.1 Financial and financing exposure

Kry's 2024 annual report describes a business still moving toward profitability rather than one that has reached self-funding. Consolidated net sales increased to SEK 2,497 million, but operating margin remained negative and the Group reported negative cash flow. Management links the improvement in cash flow to new convertible and debt financing, so the path to positive EBITDA remains dependent on execution and capital structure. The accounts report SEK 239 million of Group cash and cash equivalents at year-end and SEK 867.633 million of interest-bearing liabilities. This creates a financing and refinancing risk even though the board judged the going-concern plan implementable. Secondary-market providers also warn that private-company valuation and liquidity are uncertain; those pages are not evidence of a current transaction price. Monitoring should therefore focus on cash conversion, debt terms, covenant headroom, and whether positive EBITDA is sustained without incremental capital.[CR001, CR002, CR003, CR004, CR005]

7.2 Regulatory, legal, and data exposure

Kry's annual report discloses two active Swedish reimbursement disputes after year-end. Region Skåne terminated a midwife-clinic agreement and sought SEK 18.8 million, while Region Stockholm demanded SEK 48 million over consultations it says were compensated twice. Kry disputes both demands; no current disposition appears in the assigned evidence. The report also lists regulatory healthcare, legal and contract, production, technology, and information-security risks, and says policy changes can significantly affect the company across publicly funded systems. The UK app listing states that the service is CQC-regulated and confidential, while its privacy disclosure lists sensitive identity-linked data. These statements describe controls and exposure, not proof that controls are effective. Diligence should obtain the regional case files, current registrations, audit results, data-processing agreements, incident logs, material complaints, and litigation searches by jurisdiction. The absence of a surfaced incident in this pool is not evidence that no incident occurred.[CR006, CR007, CR008, CR009, CR010, CR016]

7.3 Operational and service reliability

Kry's operating model spans an app, video and chat consultations, physical clinics, partner clinics, clinicians, external healthcare services, and a mature electronic medical-record platform. The company's engineering job listing describes integrations with e-prescription systems, population registries, SMS gateways, and appointment-booking platforms, and calls the platform mission-critical for patient care. That breadth increases the number of failure points where outages, booking defects, data-integrity errors, or clinician-availability constraints could disrupt care. Independent app telemetry reports 2.6 million installs and a 4.57 rating from about 61 thousand ratings, but individual reviews describe missed calls, missed appointments, rebooking, and availability failures. The evidence supports a monitorable reliability risk, not a measured incident rate. Management should provide service-level metrics by market, appointment completion and rebooking rates, severity-one incident history, recovery times, and clinician capacity by channel.[CR006, CR008, CR009, CR011, CR012, CR013]

7.4 Dependencies, residual exposure, and thesis-break triggers

Kry's own accounts identify exposure to public-health policy, foreign-exchange movements, contractual counterparties, technology, and information security. The 2024 report says exchange-rate movements against the euro and pound affected earnings, and its revenue policy describes partner consultations and payments from regions, insurers, and other customers. The available evidence does not disclose customer concentration, renewal rates, supplier concentration, or the terms and covenants of the debt and convertible facilities. Those omissions matter because a hybrid-care network can appear diversified by geography while remaining concentrated by payer, regulator, platform dependency, or key clinical workforce. A thesis-break condition is a return to sustained negative EBITDA accompanied by falling cash or a new financing need on materially worse terms. Other triggers are a material regulatory restriction, a reportable privacy or clinical-safety event, repeated severe booking failures, or loss of a major payer or partner without replacement capacity. Until those indicators are disclosed and tracked, the residual risk rating should remain high.[CR004, CR005, CR011, CR014, CR015]

7.5 Exhibits

8.1 Operating proof is improving, but the financing anchor is stale

Kry's 2024 company release reports SEK 2.5bn of group revenue, EBITDA of SEK -505m versus SEK -960m in 2023, and an EBITDA margin improvement from -19.5% to -4.4%. It also says all markets returned a profit at the end of 2024, while acknowledging that the company remains on a path toward group profitability. Independent coverage adds an important qualification: country-level profitability does not equal group profitability, and the group has continued to invest in technology. This is meaningful operating progress, not proof of positive consolidated cash generation. The only explicit valuation mark in the retained pool is CNBC's April 2021 report of a $300m round at a $2bn valuation; it is a historical financing reference, not a current entry price. The public evidence does not disclose a 2025 or 2026 round, current share price, liquidation preferences, or governance rights.[CV001, CV002, CV003, CV004, CV005, CV008]

8.2 Scale and business-model evidence support the upside case, not a multiple

Kry has a credible hybrid-care scale story. Its current company materials describe operations in Sweden, Norway, France, and the UK, around 60 physical facilities, and more than 14 million consultations; another company profile reports 72 clinics and more than 200,000 consultations per month, showing that even company-reported operating snapshots are not perfectly reconciled. Sacra describes three revenue mechanisms—video consultations, SaaS sold to doctors, and referral payments—and reports a 2022 revenue mix concentrated in Sweden. These disclosures support a model with recurring payer exposure and operating leverage potential, but they do not supply a comparable-company multiple or a normalized margin base. The retained evidence includes telehealth public-market drawdowns and regional competitors, but those are context for risk and comparability rather than a defensible mark for Kry. A valuation method should therefore wait for a reconciled revenue definition, contribution margin by market and channel, and current financing data.[CV006, CV007, CV009, CV010, CV011, CV012]

8.3 Scenarios are asymmetric because current price and terms are unavailable

The bull case is operational rather than multiple-driven: the 2024 margin improvement continues, country-level profitability becomes consolidated profitability, and the hybrid digital/physical model converts consultation scale into durable payer economics. The base case assumes continued growth with unresolved group-level losses, uneven market economics, and no evidence that the 2021 financing mark remains supportable. The bear case combines renewed funding needs, a down-round or preference overhang, slower commercialization, and multiple compression after the post-COVID telehealth reset described by Sacra. Probability signals are qualitative because the pool contains no current cap table, cash balance, debt schedule, or observable transaction price. Ranges are therefore intentionally withheld. The appropriate decision variable is an entry-price discount to a diligence-confirmed intrinsic value, not a stale headline valuation.[CV003, CV004, CV007, CV008, CV013, CV014]

8.4 Track pending price, terms, and consolidated economics

The recommendation is track, with medium-low confidence in the valuation call and high risk. The company has substantial operating evidence and a plausible route to better economics, but the evidence is insufficient to say whether a buyer would be receiving that improvement at a reasonable price. EquityZen confirms that secondary liquidity can be offered through existing shareholders and that exits depend on an IPO, merger, acquisition, or eligible secondary transaction; this describes access mechanics, not a current Kry clearing price. Dealroom also states that some cap-table data are hidden and that its percentages are indicative. Before upgrading, diligence should obtain the latest financing documents, fully diluted capitalization, preference and anti-dilution terms, cash and debt schedule, monthly contribution margins, clinician utilization, payer concentration, and reconciled consultation and revenue KPIs. Exit readiness is not established by marketplace availability alone.[CV002, CV008, CV012, CV013, CV015, CV016]

8.5 Exhibits